Komori
EnBio Holdings,Inc (6092) · TargetRestated

Performance-linked share acquisition rights with targets of ¥8.5 billion in consolidated net sales and ¥500 million in net income

First written in FY2017-Q1. 2 of 4 entries say "Restated". Latest entry: FY2022.

4entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017-Q1 – FY2017AdvancedFY20192016: 120162017: 120172018: 020182019: 120192020: 020202021: 020212022: 12022
Same theme, other companies

0 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2022RestatedAnnual report

    「(a) If consolidated net sales in any fiscal year are at least ¥8.5 billion Exerciseable percentage: 50% (b) If net income attributable to owners of the parent in any fiscal year is at least ¥500 million Exerciseable percentage: 50%」

    The conditions for performance-linked stock acquisition rights based on consolidated net sales of ¥8.5 billion and net income attributable to owners of the parent of ¥500 million are restated.
  2. FY2019AdvancedAnnual report

    「Consolidated net sales for the current consolidated fiscal year increased 2.1% from the previous consolidated fiscal year to ¥8,563,053 thousand, marking the fourth consecutive fiscal year of higher net sales.」

    The net sales condition for the performance-linked stock acquisition rights, requiring consolidated net sales of at least ¥8.5 billion, was met with net sales of ¥8,563,053 thousand in the fiscal year ended March 2019. Meanwhile, the condition requiring net income attributable to owners of the parent of at least ¥500 million was not met.
  3. FY2017RestatedAnnual report

    「(a) If consolidated net sales in any fiscal year are at least ¥8.5 billion 50% of the stock acquisition rights allocated to each holder (b) If net income attributable to owners of the parent in any fiscal year is at least ¥500 million 50% of the stock acquisition rights allocated to each holder」

    The exercise conditions covering the fiscal years ending March 2017 through March 2019, based on net sales of ¥8.5 billion and net income attributable to owners of the parent of ¥500 million, are restated.
  4. FY2017-Q1First statedAnnual report

    「If, in any fiscal year from the fiscal year ending March 2017 through the fiscal year ending March 2019, consolidated net sales and net income attributable to owners of the parent satisfy both or either of the following conditions, the holders of the stock acquisition rights may exercise the stock acquisition rights allocated to them, up to the percentage specified for each condition: (a) If consolidated net sales in any fiscal year are at least ¥8.5 billion, 50% of the number of stock acquisition rights allocated to each holder; (b) If net income attributable to owners of the parent in any fiscal year is at least ¥500 million, 50% of the number of stock acquisition rights allocated to each holder.」

    A new exercise condition for stock acquisition rights issued to officers and employees was disclosed: in any fiscal year from the fiscal year ending March 2017 through the fiscal year ending March 2019, consolidated net sales of at least ¥8.5 billion or net income attributable to owners of the parent of at least ¥500 million.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for EnBio Holdings,Inc yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.